DMT1/SLC11A2 Antibody (Mouse mAb) [G3J24]

Catalog No.: F0991

    Application: Reactivity:
    • Lane 1: A549, Lane 2: A549 (KO DMT1)
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:600
    1:2000
    Application
    WB, IHC, FCM
    Source
    Mouse Monoclonal Antibody
    Reactivity
    Human, Mouse
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    62 kDa 80 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Mouse duodenum tissue; Human endometrium cancer tissue; SH-SY5Y cells; A549 cells
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    DMT1/SLC11A2 Antibody (Mouse mAb) [G3J24] detects endogenous levels of total DMT1/SLC11A2 protein.
    タンパク質の局在
    細胞膜、エンドソーム、ゴルジ装置
    Uniprot ID
    P49281
    Clone
    G3J24
    Synonym(s)
    DCT1, DMT1, NRAMP2, OK/SW-cl.20, SLC11A2, Natural resistance-associated macrophage protein 2, NRAMP 2, Divalent cation transporter 1, Divalent metal transporter 1, Solute carrier family 11 member 2, DMT-1
    Background
    Divalent metal transporter 1 (DMT1, also known as SLC11A2, NRAMP2, or DCT1) is a proton‑coupled divalent cation transporter that serves as the principal transmembrane route for ferrous iron uptake at the apical border of duodenal enterocytes and for iron exit from transferrin endosomes in multiple cell types, placing it at the core of non‑heme iron acquisition and cellular iron handling. The protein is a multipass membrane transporter with twelve predicted transmembrane helices and cytosolic N‑ and C‑termini, and alternative splicing and differential use of iron‑responsive elements generate isoforms with distinct subcellular localization and post‑transcriptional regulation, allowing DMT1 to operate both at the plasma membrane and on endosomal membranes in tissue‑specific patterns. Transport activity couples inward proton movement to uptake of divalent metals, with highest preference for Fe²⁺ and a pH optimum in the mildly acidic range that matches the duodenal lumen and endosomal compartments, and DMT1 also carries Mn²⁺ and other first‑row transition metals with lower selectivity, providing a shared pathway for nutritionally essential and potentially toxic metals. At the intestinal brush border, ferrireductases and dietary reductants convert luminal Fe³⁺ to Fe²⁺, which DMT1 then transports into enterocytes, while on the transferrin cycle endosomes in erythroid precursors and other cells, DMT1 mediates release of Fe²⁺ from endosomes into the cytosol after transferrin‑bound iron is reduced, supplying iron for heme synthesis, iron–sulfur cluster assembly, and iron storage. Expression of DMT1 responds to intracellular iron status through iron‑responsive element–dependent and –independent mechanisms and is modulated by systemic regulators of iron metabolism, aligning transporter abundance with body iron demand and integrating DMT1 into the hepcidin–ferroportin axis of iron homeostasis. DMT1 is also present in brain microvascular endothelium, neurons, and glia, where it is implicated in iron entry across the blood–brain barrier, neuronal iron uptake, and manganese transport, creating a link between DMT1 function, regional brain iron loading, and the vulnerability of dopaminergic and other neuronal populations to oxidative stress in aging and neurodegeneration. Mutations or functional depletion of DMT1 in rodents cause hypochromic microcytic anemia with impaired intestinal iron absorption and defective erythroid iron utilization, while the characterized human loss‑of‑function mutation produces severe anemia with abnormal iron handling in erythroid cells, underscoring the requirement for DMT1‑mediated ferrous iron transport for both dietary uptake and erythropoiesis. In contrast, increased DMT1 expression or activity is associated with iron overload in select tissues and with elevated brain iron and manganese in experimental models, where excess metal accumulation contributes to mitochondrial dysfunction, reactive oxygen species formation, and neurodegenerative changes, and DMT1 has been implicated as a contributor to the iron and manganese imbalance observed in disorders such as Parkinson’s disease and other neurodegenerative conditions.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください